


Please type a plus sign (+) inside this box → ☐



PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Compl t if Kn wn	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	5604-D1-01-RG
		Filing Date	10/14/2000
		First Named Inventor	Annette Marian Doherty, et al.
		Group Art Unit	1653
		Examiner Name	D. Lukton
		Attorney Docket Number	5604-D1-01-RG
Sheet	2	of	2

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
DL		HIROSUKE KOUCHI, et al, "Manumycin A, Inhibitor of ras Farnesyltransferase Inhibits Proliferation and Migration of Rat Vascular Smooth Muscle Cells", Biochemical and Biophysical Research Communications, 1999, pp 915-920, Vol., 264, No. 3, Academic Press	
DL		TAKESHI NAGASU, et al., "Inhibition of Human Tumor Xenograft growth by treatment with the Farnesyl Transferase Inhibitor B956", cancer Research, November 15, 1995, pp 5310-5314, Vol. 55, No. 22	

Examiner Signature		Date Considered	5/4/03
--------------------	--	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

[illegible]